Human Genome Epidemiology Literature Finder
|
Records 1 - 5 (of 5 Records) |
| Query Trace: Counseling and DRD2[original query] |
|---|
| Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2003 Sep 22 (5): 541-8. Lerman Caryn, Shields Peter G, Wileyto E Paul, Audrain Janet, Hawk Larry H, Pinto Angela, Kucharski Susan, Krishnan Shiva, Niaura Ray, Epstein Leonard |
| The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2004 Apr 6 (2): 229-39. Cinciripini Paul, Wetter David, Tomlinson Gail, Tsoh Janice, De Moor Carl, Cinciripini Lynn, Minna Jo |
| Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. The pharmacogenomics journal 2005 5 (1): 21-9. Swan G E, Valdes A M, Ring H Z, Khroyan T V, Jack L M, Ton C C, Curry S J, McAfee |
| Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2007 Aug 9 (8): 821-33. David Sean P, Brown Richard A, Papandonatos George D, Kahler Christopher W, Lloyd-Richardson Elizabeth E, Munafò Marcus R, Shields Peter G, Lerman Caryn, Strong David, McCaffery Jeanne, Niaura Raymo |
| A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2008 Jan 10 (1): 231-40. Welton Nicky J, Johnstone Elaine C, David Sean P, Munafò Marcus |
- Page last reviewed:Feb 1, 2024
- Content source: